New York, NY (PRWEB) August 28, 2013
The diabetes drug resource center at DrugRisk.com is announcing updated information for patients taking the medication Byetta. A federal panel is considering consolidation of a growing number of lawsuits alleging the drug caused pancreatic cancer or thyroid cancer*.
DrugRisk is a resource center created to give those taking popular prescription drugs the latest information on recalls, safety alerts, research and litigation news. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.
Byetta is a popular injectable medication prescribed to those with type-II diabetes to lower blood sugar levels. However, the resource center has added information showing experts disagree about its safety.
In 2011, a study from UCLA suggested subjects given Byetta may have higher occurrences of pancreatic cancer and thyroid cancer**. This year, the Journal for the American Medical Association also advised that drugs like Byetta can double the risk of pancreatitis, a major risk factor for pancreatic cancer***.
However, the FDA recently advised there is not enough information at present to link drugs like Byetta to cancer or require new warning labels****.
Now, DrugRisk has learned that, due to the growing number of patients who have filed a Byetta lawsuit alleging cancer, the Judicial Panel on Multidistrict Litigation is deciding whether to consolidate cases to a special federal court*. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).
Anyone affected by cancer after taking Byetta is encouraged to visit the DrugRisk center or speak with a lawyer about their legal options. However, DrugRisk only recommends lawyers who have already handled these complex Byetta lawsuits.
For more information on the research, side effects and litigation news related to Byetta and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*JPML, 6/12/13; jpml.uscourts.gov/sites/jpml/files/Hearing_Order-7-25-13.pdf
**Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
***JAMA Internal Medicine, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537
****Pharmalive 7/30/13; pharmalive.com/fda-decides-no-risk-of-pancreatic-cancer-with-diabetes-drugs